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Common polymorphisms in complement alternative pathway (AP)
proteins C3 (C3R102G), factor B (fBR32Q), and factor H (fHV62I) are
associated with age-related macular degeneration (AMD) and
other pathologies. Our published work showed that fBR32Q inﬂu-
ences C3 convertase formation, whereas fHV62I affects factor I co-
factor activity. Here we show how C3R102G (C3S/F) inﬂuences AP
activity. In hemolysis assays, C3102G activated AP more efﬁciently
(EC50 C3102G: 157 nM; C3102R: 191 nM; P < 0.0001). fB binding ki-
netics and convertase stability were identical, but native and
recombinant fH bound more strongly to C3b102R (KD C3b102R: 1.0
μM; C3b102G: 1.4 μM; P < 0.0001). Accelerated decay was unal-
tered, but fH cofactor activity was reduced for C3b102G, favoring
AP ampliﬁcation. Combining disease “risk” variants (C3102G, fB32R,
and fH62V) in add-back assays yielded sixfold higher hemolytic
activity compared with “protective” variants (C3102R, fB32Q, and
fH62I; P < 0.0001). These data introduce the concept of a functional
complotype (combination of polymorphisms) deﬁning comple-
ment activity in an individual, thereby inﬂuencing susceptibility
to AP-driven disease.
inﬂammation | infection
Complement plays crucial roles in clearance of pathogens andimmune complexes (1), with alternative pathway (AP) “tick-
over” in plasma providing a rapid response (2). Assembly of theAP
C3-cleaving enzyme (convertase) involves Mg2+-dependent bind-
ing of factor B (fB) to C3b, forming the labile proenzyme C3bB;
factor D (fD) then cleaves fB to yield active convertase (C3bBb).
Convertase-generated C3b forms more C3bBb, providing expo-
nential AP ampliﬁcation. C3b clustered around the convertase
creates a C5-cleaving enzyme (C3bBbC3b), triggering formation of
the cytolytic membrane attack complex (MAC).
Nascent C3b binds pathogens and host cells indiscriminately.
To prevent damage to self, multiple regulatory proteins limit
complement activation by inactivating C3b/C4b, dissociating the
C3/C5 convertases, or inhibiting MAC formation. Decay accel-
erating factor (DAF) (CD55) dissociates convertases, whereas
membrane cofactor protein (MCP) (CD46) is an essential co-
factor for factor I (fI) cleavage of C3b (3). In plasma, AP am-
pliﬁcation is controlled by factor H (fH), which rapidly dissociates
the enzymatic Bb domain from the C3 convertase and catalyses fI
cleavage of C3b (4).
Maintenance of complement homeostasis involves equilibrium
between activation and control. AP dysregulation is associated
with many diseases (5), either due to loss-of-function/expression
mutations in regulators or gain-of-function mutations in com-
ponents; both scenarios cause uncontrolled complement activa-
tion and inﬂammation (6–10). Common polymorphisms in AP
components (C3 and fB) and regulators (fH) also link to disease;
the fH polymorphism fHY402H (rs1061170) is risk for age-related
macular degeneration (AMD) (11–14), whereas fH62I (rs800292)
and fB32Q (rs641153) polymorphisms are protective (11, 15, 16).
A common polymorphism in C3, originally identiﬁed from
electrophoretic mobility and dubbed C3S/F for slow/fast migra-
tion (17) (C3R102G, rs2230199; allele frequency: C3102R [C3S]:
0.79, C3102G [C3F]: 0.21), was recently linked with AMD (odds
ratio 2.6) (18, 19). Each polymorphism also links to other dis-
orders. fH62I is protective in dense deposit disease (DDD) and
atypical hemolytic uremic syndrome (aHUS) (15), whereas fB32Q
is risk for infections (20) and overrepresented in autoimmunity
(21, 22).C3R102G is associatedwith IgAnephropathy (23), systemic
vasculitis (24), kidney allograft dysfunction (25), and DDD (26).
Understanding mechanisms underlying these genetic associa-
tions is essential to prove causality, eliminate association through
linkage, and aid understanding of disease etiology. The fH402H
risk variant had no direct effect on fH AP regulation but inﬂu-
enced binding to sialylated surfaces (27, 28). The AMD-pro-
tective variant, fB32Q, formed AP convertase less efﬁciently,
whereas the protective variant fH62I bound C3b more strongly
and was a better cofactor for fI inactivation (29). These latter
polymorphisms directly inﬂuenced AP activity, explaining their
link to disease. Effects were additive, “risk” combinations (fB32R/
fH62V) caused twofold increased AP activation compared with
“protective” variants (fB32Q/fH62I) (29). To deﬁne mechanisms
underlying disease associations of the common C3R102G (C3S/F)
polymorphism, proteins were puriﬁed from homozygote donors
and tested for ligand binding, convertase formation, and regu-
lation. The AMD risk variant (C3b102G) bound fH less well
compared with C3b102R, causing decreased fI cofactor activity,
extended convertase lifetime, and enhanced AP ampliﬁcation.
By combining risk and protective AP variants, a “complotype”
was revealed in which C3, fH, and fB variants collaborate to
set levels of AP activity in plasma, thereby inﬂuencing risk in
complement-dependent diseases.
Results
Differential Activity of C3R102G Variants in Hemolysis Assays.C3, from
plasma of healthy individuals homozygous for C3102R (n = 3) or
C3102G (n = 2) and free of hydrolyzed C3 and aggregates, was
added back to normal human serum depleted of C3 (NHSΔC3)
and used to deposit C3b and AP convertases on antibody-coated
sheep erythrocytes (ShEA); lysis was developed using C3-sup-
plemented methylamine-treated NHS (NHS-MA). NHSΔC3
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supplemented with C3102R required 1.3-fold more fB to achieve
lysis equivalence with C3102G-supplemented NHSΔC3, demon-
strating that plasma containing C3102G (AMD risk) displayed
higher AP activity (Fig. 1). EC50 (fB) values were internally
consistent for different C3102G (158 nM and 156 nM), and
C3102R (188 nM, 197 nM, and 187 nM) donors, and were sig-
niﬁcantly different (two-tailed, unpaired t test; P < 0.0001).
Formation and Decay of C3b102G and C3b102R AP Convertases. To
explore molecular mechanisms underlying differential hemolytic
activity, formation and natural decay of the AP C3 convertase
was analyzed using surface plasmon resonance (SPR) (Biacore).
AP C3 convertase formed on Biacore chips replicates natural
convertase: it is labile, cleaves C3, deposits nascent C3b, and is
regulated by decay accelerators (30, 31). Either fB alone, or fB
and fD together, were ﬂowed over each C3b variant. Neither
proenzyme (C3bB; Fig. S1; KD C3b102G: 0.85 ± 0.10 μM (n = 5);
KD C3b102R: 0.71 ± 0.15 μM (n = 5); two-tailed, unpaired t test;
P = 0.11) nor convertase (C3bBb; Fig. S2; KD C3b102G: 67 ± 7
nM, n = 10; KD C3b102R: KD: 71 ± 8 nM, n = 18; two-tailed,
unpaired t test; P = 0.23) formation differed signiﬁcantly be-
tween variants. Both enzymes decayed at the same rate with
calculated half-lives at 25 °C (ln2/kd) of 369 ± 35 s for C3b102G Bb
and 385 ± 33 s for C3b102RBb (two-tailed, unpaired t test; P =
0.06). In multiple experiments using C3b102G and C3b102R from
different donors, run on different days and chip surfaces, results
were consistent. The fB32R variant was used in all analyses.
Binding of Convertase Regulators to C3bR102G Variants. After con-
vertase decay, residual C3b is a ligand for cofactors, fH and
MCP, which catalyze cleavage/inactivation by fI. C3b interaction
with regulators was assessed using SPR. Each variant C3b was
coupled to the Biacore chip, and native fH ﬂowed across (Fig. 2
A and B). Binding afﬁnity (KD) of fH for C3b102G at steady-state
equilibrium (Fig. 2 A and B, Inset), was 1.3-fold lower than for
C3b102R (KD = 1.36 ± 0.17 μM, n = 17; KD = 1.03 ± 0.09 μM,
n = 16; P < 0.0001; Fig. 2C). Analyses were reproduced with
native fH from three different donors and repeated at least three
times on different chips and days and with protein from two
C3b102G and three C3b102R donors. The fH62V variant was used
throughout these analyses. Binding of fH to immobilized C3
(H2O)102R and C3(H2O)102G (hydrolyzed C3) was measured in
identical experiments; measured afﬁnities were reduced com-
pared with C3b and were not signiﬁcantly different for the var-
iants [C3(H2O)102R, KD = 8.85 ± 0.64 μM; C3(H2O)102G, KD =
9.02 ± 0.13 μM; P = 0.727; Fig. S3].
C3b binding analyses were repeated using recombinant fH
comprising short consensus repeats (SCRs) 1-4 (rfH1–4) to in-
vestigate whether the observed afﬁnity difference was due to
differential binding of SCRs 1–4, containing fH decay and co-
factor activities (32, 33). rfH1–4 bound C3b102G with 1.3-fold
lower afﬁnity than C3b102R (KD = 10.2 ± 1.0 μM, n = 5 versus
KD = 7.7 ± 0.7 μM, n = 6; P < 0.0001; Fig. 2 E and F), repli-
cating ﬁndings with native fH. Binding afﬁnities of soluble
recombinant MCP (sMCP) and soluble recombinant DAF
(sDAF) for immobilized C3b variants were measured precisely as
described for fH. There was no difference in C3b variant binding
afﬁnities of either sMCP (KD C3b102G = 1.48 ± 0.24 μM, n = 11;
KD C3b102R = 1.43 ± 0.23 μM, n = 6; P = 0.68; Fig. S4 A–C) or
sDAF (KD C3b102G 12.2 ± 1.7 μM, n = 19; C3b102R KD = 12.8 ±
1.2 μM, n = 10; P = 0.39; Fig. S4 D–F).
To test effects of C3R102G polymorphism on convertase ac-
celerated decay, different concentrations of sDAF, native fH and
rfH1–4 were ﬂowed over C3b102GBb or C3b102R Bb-coated sur-
faces to catalyze rapid decay of Bb (30, 31) (Fig. 3 A–C). The
convertases showed identical susceptibility to accelerated decay
by each regulator. Cofactor activity for fI cleavage was not
tractable using Biacore because mass change from C3b to iC3b
(C3f release) was not measurable.
Hemolysis Assays to Investigate Decay and Cofactor Activities of fH
on Variant Convertases. fH and rfH1–4 bound less well to C3b102G
compared with C3b102R, but reduced binding afﬁnity did not
cause decreased decay acceleration. To conﬁrm this ﬁnding and
test whether afﬁnity differences affected fI cofactor activity,
hemolysis assays were performed using C3 variants spiked into
NHS depleted of C3, fH, and fB (NHSΔC3BH) to deposit C3b
on ShEA. AP convertase was then assembled using fB and fD
and incubated with different fH concentrations to promote
convertase decay before developing lysis (Fig. 3D). No difference
in rate of accelerated decay of the variant convertases was seen,
in agreement with Biacore data (IH50 for C3102G: 4.4 ± 0.2 nM;
C3102R: 4.0 ± 0.5 nM; P = 0.31).
Cofactor activity was measured by treating C3b-coated ShEA
with fI and different concentrations of fH to inactivate C3b. Con-
vertasewas formedon residualC3b and lysis developed. TheC3102R
variant showed 1.5-fold higher sensitivity to inactivation by fI com-
pared with C3102G when fH62I was used as cofactor (IH50: 1.5 ± 0.2
nMforC3b102R; 2.3±0.1nMforC3b102G; two-tailedunpaired t test;
P< 0.001) and 1.7-fold higher sensitivity to inactivation catalyzed by
fH62V (IH50: 3.6 ± 0.1 nM for C3b102G; 2.2 ± 0.1 nM for C3b102R;
two-tailedunpaired t test;P<0.0001;Fig. 3E). Strikingly, combining
two protective variants (C3102R and fH62I) caused a 2.4-fold re-
duction in ShEA lysis compared with risk combination (C3102G and
fH62V; two-tailed unpaired t test; P < 0.0001; Fig. 3E).
Different Combinations of Polymorphic Variants of C3, fH, and fB
Regulate AP Activity in Plasma. Data above show that different
combinations of fH and C3 variants yield different plasma AP
activities. We previously showed that fB32Q forms C3 convertase
less efﬁciently than fB32R, causing decreased AP ampliﬁcation
(34). To test whether C3 and fB variants collaborate to inﬂuence
AP activity, NHS depleted of C3 and fB (NHSΔC3B) spiked with
C3 variants was used to deposit variant C3b on ShEA. Con-
vertase was then formed by incubating with fD and either fB32R
or fB32Q and lysis developed (Fig. 4A). Complementary effects of
C3 (ﬁlled/open symbols) and fB (circles/squares) variants were
apparent; protective combination requiring 3.2-fold more fB to
achieve lysis comparable with risk combination (EC50: C3102G,
fB32R: 46.5 ± 2.8 nM; C3102R, fB32Q: 149.1 ± 1 nM; P < 0.0001).
Complementarity of the fHV62I polymorphism was investigated
by comparing the variant set promoting most AP ampliﬁcation
(C3102G/fB32R/fH62V) with that causing least ampliﬁcation
(C3102R/fB32Q/fH62I). C3 variants spiked into NHSΔC3BH were
used to deposit C3b on ShEA (depletion of fH eliminated C3b
cleavage by fI), followed by incubation with equivalent concen-
trations of either fH variant and fI, and ﬁnally varying amounts of
fB variants and fD to form convertase. Lysis was developed and
Fig. 1. Hemolytic activity of the C3 variants C3102G and C3102R. C3 was pu-
riﬁed from plasma of two donors homozygous for C3102G (circles) and three
donors homozygous for C3102R (squares/diamond) and was added to C3-
depleted serum to deposit C3b on ShEA. C3 convertase was formed and lysis
was developed using NHS-MA supplemented with C3 of each variant. Data
points represent mean ± SD of triplicate measurements. Curves were ﬁtted
using nonlinear regression to calculate the EC50.
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hemolysis measured (Fig. 4B). The C3102G/fB32R/fH62V combi-
nation had sixfold greater AP hemolytic activity compared with
C3102R/fB32Q/fH62I at equivalent concentrations and in identical
depleted serum (EC50 50± 1 nM versus 289± 14 nM, P< 0.0001).
Thisﬁndingwas conﬁrmed inwhole serumAPhemolysis by adding
back pure C3, fB, and fH variants to hydrazine-treated NHS de-
Fig. 3. Regulatory activities of native fH, rfH1–4, and sDAF on surface-bound convertase formed from C3R102G variants. (A–C) Identical amounts (1,500 RU) of
C3b102R (gray dotted line) and C3b102G (black solid line) were deposited on the chip surfaces using thioester coupling. Convertase was formed by ﬂowing
(20 μL/min) fB and fD in the presence of Mg2+ and allowed to decay naturally for 150 s. At the arrow, either (A) sDAF (10, 30, 100, and 300 nM; from Upper to
Lower curve), (B) fH (30, 100, and 300 nM), or (C) rfH1–4 (30, 100, 300, and 1,000 nM) was injected (90 s) and accelerated decay of the convertase was
monitored. Inset shows whole sensorgram; expanded decay curves are illustrated. (D) Decay accelerating activity of fH was quantitated by incubating C3b-
coated ShEA with fB and fD to form convertase and then treating with varying concentrations of fH to decay convertase before developing lysis. (E) Cofactor
activity was analyzed by treating C3b-coated ShEA with fH and fI before forming convertase and developing lysis. In D and E, curves were ﬁtted using
nonlinear regression to calculate the IH50. Data points represent mean ± SD of three determinations. C3b102G-ShEA are shown as circles, C3b10R-ShEA as
squares, fH62V as ﬁlled symbols, and fH62I as open symbols.
Fig. 2. Binding of native fH and recombinant fH to C3bR102G variants. Native fH (A and B) or rfH1-4 (D and E) were ﬂowed over immobilized C3b102G (A and
D) or C3b102R (B and E) at concentrations between 45 nM and 2.9 μM (fH) and 80 nM–23 μM (rfH1–4) and equilibrium binding response was measured. Afﬁnity
(KD) was determined by steady-state analysis (Inset). Multiple analyses on different days with different donors conﬁrmed consistent and signiﬁcant differ-
ences in native fH (C) or rfH1-4 (F) binding to the C3bR102G variants.
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pleted of fB and fH (NHS-R3ΔBH). AP serum hemolytic activity
(AH50) of serum repleted with C3102G/fB32R/fH62V was 206 units/
mLcomparedwith 108 units/mLwhen repletedwithC3102R/fB32Q/
fH62I.
Discussion
Common polymorphisms in complement proteins alter risk for
diverse diseases (11, 15, 16, 19). Polymorphisms in AP proteins
C3, fB, and fH strongly inﬂuence risk for AMD with quoted odds
ratios for homozygotes of 3.51–7.4 for fHY402H (11, 14), 2.6 for
C3R102G (19), 0.36 for fBR32Q (16), and 0.54 for fHV62I (11); each
also inﬂuences risk for other diseases and/or infections, implying
that small changes in AP proteins can dramatically affect health.
fHY402H likely alters capacity of fH to bind surfaces (27, 28), but
the reasons why other AP polymorphisms inﬂuence disease
susceptibility were unknown until our demonstration that fBR32Q
and fHV62I directly impacted on AP activation and ampliﬁcation
(29, 34). Association of the common C3 polymorphism (C3S/F;
C3R102G) with disease has been recognized for decades, but the
molecular basis was enigmatic. We report here that the C3R102G
polymorphism affects AP activation by inﬂuencing efﬁciency of
regulation by fH and that different combinations of common
variations in C3, fB, and fH dramatically alter AP activity, up to
sixfold at the extremes when pure proteins were used in the as-
say. When variants were added back to whole serum, the C3102R,
fB32Q, fH62I combination of variants had 50% alternative path-
way activity (AH50) compared with the most active variants.
These data reveal an AP complotype providing clear explanation
for association of AP protein polymorphisms with disease.
Given the long association of C3R102G with disease, it is sur-
prising that the functional basis had remained unknown; however,
our studies of polymorphisms in fB and fH had demonstrated that
functional consequences of the C3R102G polymorphism were
likely to be subtle (29, 34). Meticulous attention was therefore
given to protein purity and integrity, with replication using pro-
tein from several homozygous individuals. Pure protein added
back to C3-depleted serum was used to deposit C3b and assemble
AP convertase on ShEA, before developing lysis. AP hemolytic
activity driven by the C3102R convertase was consistently less than
by C3102G convertase (Fig. 1). This was not due to differences in
kinetics of convertase formation or decay, but to altered suscep-
tibility to regulation. Speciﬁcally, fH bound C3b102G with lower
afﬁnity compared with C3b102R (Fig. 2 A–C). This difference was
replicated using recombinant fH SCRs 1–4, locating differential
binding in these amino-terminal domains where decay and co-
factor activities reside (Fig. 2 D–F) (32, 33). Decay accelerating
activity of fH was not affected by this change in afﬁnity (Fig. 3 B–
D), but fI cofactor activity for C3b102G inactivation was reduced,
decreasing the rate of C3b inactivation and increasing overall AP
activity (Fig. 3E). The effect was speciﬁc for fH as binding afﬁn-
ities and regulatory control by DAF and MCP were unaffected by
the C3bR102G polymorphism. Binding afﬁnity of fH for hydrolyzed
C3 was weak and showed no difference for the C3(H20)R102G
variants; thus, the polymorphism affects primarily the ampliﬁcation
convertase rather than the initiation convertase and tickover loop.
The observation that a reduction in binding afﬁnity between
C3b and fH adversely affected cofactor but not decay accelerating
activity implies that cofactor activity is more dependent on tight
binding, an interpretation supported by our published analyses
of fHV62I, where lower binding afﬁnity for C3b in fH62V reduced
cofactor but not decay activities compared with fH62I (29).
C3R102G polymorphismmaps to a positively charged area at the in-
terface between the MG1 domain and TED (thioester-containing
domain) (Fig. S5) (35). fH SCR3 binds MG2 and SCR4 contacts
TED in close proximity to MG1. Decreasing overall positive
charge in C3b by substituting Arg with Gly at position 102 likely
alters interdomain associations around the fH binding site, inﬂu-
encing afﬁnity and cofactor activity. In contrast, binding of fB
involves different C3b domains; hence, convertase assembly and
decay are unaffected by the polymorphism (Fig. S5) (36, 37).
The C3R102G functional effect, modest in isolation, when placed
in the context of other AP variants, translates to a large functional
effect. C3R102G and fHV62I polymorphisms both inﬂuence cofactor
activity, and effects were additive (Fig. 3E), as were effects of
C3R102G and fBR32Q variants (Fig. 4A).Comparisonof theprotective
set (C3102R, fB32Q, fH62I) with risk (C3102G, fB32R, fH62V) revealed a
sixfold difference in hemolytic activity, graphically illustrating that
different combinations of complement polymorphic variants yield
dramatic differences in complement activity (Fig. 4B). We demon-
strate that different combinations of activators and regulators (the
complotype) set the level of systemic complement activity in an in-
dividual, thereby determining risk for various pathologies involving
complement. These ﬁndings provide functional underpinning to
genetic analyses describing altered disease risk depending on the
set of complement genes inherited (38, 39). Maintenance of com-
plement homeostasis involves a balance between activation and
regulation. Inheritance of a highly active complement system (e.g.,
homozygous C3102G, fB32R, fH62V), whereas beneﬁcial in ﬁghting
infection by enhanced opsonization, may predispose to pathology
in inﬂammatory diseases such as AMD.
The extreme risk and protective complotypes illustrated here
will be rare but they represent the extremities of a continuum in
AP activity that deﬁne disease risk. Biomarker studies reported
complement activation products in AMD plasma, indicative of
low-grade, systemic AP activation (39–41). Inheritance of a more
active complotype may be detrimental only in the elderly, where
chronic inﬂammation has been sustained long-term, whereas
inheritance of a less active complotype, although protective
against inﬂammation, may increase susceptibility to infection,
a negative selective pressure in populations where infection is
Fig. 4. Polymorphic variations in C3, fB, and fH collaborate to control AP
hemolytic activity. (A) C3b was deposited on ShEA using NHSΔC3B spiked
with either variant of C3 (C3102R, squares; C3102G, circles); convertase was
formed using fD and either fB32R (ﬁlled symbols) or fB32Q (open symbols);
lysis was developed with NHSΔBH. (B) C3 variants were spiked into
NHSΔC3BH and used to deposit C3b on cells, which were then treated with fI
and a speciﬁc variant of fH. Convertase was formed by adding different
concentrations of a speciﬁc fB variant with fD, and lysis was developed. The
complotype predicted to yield highest AP activity (C3102G, fB32R, fH62V) is
shown by circles, whereas that predicted to yield lowest AP activity (C3102R,
fB32Q, fH62I) is represented by squares. Data points represent mean ± SD of
three determinations (error bars depicted for each point); nonlinear re-
gression was used to calculate the EC50. Inset shows SDS/PAGE of puriﬁed C3,
fB, and fH variants.
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prevalent. This is illustrated in a study of a cohort of 347 Dutch
immigrants to Surinam in the 19th century that lost 60% of their
number soon after arrival due to typhoid and yellow fever.
Survivors of these epidemics showed higher frequency of the
C3102G allele compared with the parent population (P = 0.00001),
providing evidence that strong selective pressure in the face of
infection selects this C3 variant in a population (42).
We demonstrate here that sets of common polymorphisms in
just three complement proteins dramatically alter AP activity;
however, the complotype extends beyond these proteins and the
AP. Protein levels will inﬂuence systemic complement activity, as
will polymorphisms in other complement proteins. For example,
fI- and fH-related proteins are associated with AMD (43, 44),
whereas polymorphisms in C5/TRAF1 are associated with rheu-
matoid arthritis and systemic lupus erythematosus (45, 46).
Complement dysregulation often manifests in inﬂammatory dis-
eases when there are “multiple hits,” exempliﬁed in aHUS where
two or three hits in the complement cascade are required to trigger
pathology (47). Frequently, one ormore of these hits is a mutation
in a complement protein causing overactivation of components or
decreased function of regulators; however, our data show that
the complotype can also tip the balance toward dysregulation and
pathology. An individual’s complotype will therefore inﬂuence
susceptibility to, or severity of, diseases involving complement
dysregulation; knowledge of the complotype will not only aid
disease prediction but also dictate avenues of therapy aimed at
restoring equilibrium in the complement cascade.
Materials and Methods
Preparation of Complement Components and Activation Fragments. C3, fB, and
fH were puriﬁed from plasma of consented volunteers, genotyped and homo-
zygous for the relevant protein; hydrolyzed C3was generated by hydroxylamine
treatment of pure C3 (SIMaterials andMethods). C3 variants were puriﬁed using
classical chromatography (Na2SO4 cut; anion and cation exchange), described in
SI Materials and Methods). On the day of analysis, C3 samples were dialyzed
into 50 mM Na-phosphate, pH 6, fractionated on Mono S (GE Healthcare) to
remove hydrolyzed C3, and gel ﬁltered (Superdex200 10/300; GE Healthcare) to
remove aggregates and buffer exchange [Hepes-buffered saline (HBS): 10 mm
Hepes, 150 mM NaCl], complement ﬁxation diluent (CFD) (Oxoid), AP buffer
(5 mM sodium barbitone pH 7.4, 150 mM NaCl, 7 mM MgCl2, 10 mM EGTA
pH 7.5) as appropriate, and used immediately without concentration. Factor B
and fH were afﬁnity puriﬁed from EDTA plasma on anti-Bb (mAb JC1, in-house)
or anti-fH (mAb 35H9, in-house) HiTrap columns (GE Healthcare). Eluted protein
was gel ﬁltered to remove aggregates and minor contaminants and buffer
exchange. Factor D and fI were from Comptech. C3b was prepared by ﬂuid
phase AP activation using puriﬁed proteins as described (31) and gel ﬁltered to
remove aggregates. Recombinant fH (rfH1–4) was isolated from Escherichia coli
inclusions and refolded as described in SI Materials and Methods.
Hemolysis Assays. NHS depleted of C3 (NHSΔC3), C3 and fB (NHSΔC3B), fB and
fH (NHSΔBH), or all three components (NHSΔC3BH or NHS-R3ΔBH) was pre-
pared as described previously and in SI Materials and Methods(29). NHS-MA
was prepared as described (48). Hemolysis assays were performed as described
with modiﬁcations as speciﬁed (29). Curves were ﬁtted using nonlinear re-
gression and EC50/IH50 calculated (GraphPad Prism software); statistical signiﬁ-
cance was evaluated usingMicrosoft Excel software (two-tailed unpaired t test).
Preparation of cells. C3b was deposited on antibody-coated sheep erythrocytes
(ShEA) using either 5% (vol/vol) NHSΔC3, 10% (vol/vol) NHSΔC3B (presence
of fH), or 10% (vol/vol) NHSΔC3BH (absence of fH). Puriﬁed C3 was added
back to depleted serum at either 420 nM (5% serum, Fig. 1), 790 nM (10%
serum; decay assay Fig. 3D), or 260 nM (5% serum; cofactor assay Fig. 3E).
OmCI (0.6 μM; gift from Varleigh, London, United Kingdom) was used to
block terminal pathway activation as described previously (29, 49). ShEA-C3b
cells were resuspended in AP buffer at 2% (vol/vol).
Comparison of C3 from different homozygote donors. ShEA-C3b were generated
using NHSΔC3 with C3 add-back; C3bBb was formed by incubating 1 volume
of cells with 1 volume of 16 nM fD mixed with fB (24–789 nM) for 15 min at
37 °C. Further convertase formation was prevented and lysis developed by
adding 1 volume of NHS-MA (4% vol/vol in PBS, 20 mM EDTA) containing
530 nM C3. Lysis was calculated by measuring hemoglobin release, control
incubations were ShEA incubated in buffer only (0%) or in 0.001% Triton X
(100%). Percentage lysis = 100 × (A410 test sample – A410 0% control)/(A410
100% control – A410 0% control).
fH decay and cofactor assays. These assays were performed as previously de-
scribed (29) other than serum used to deposit C3b was depleted of donor C3
and had puriﬁed C3 added-back (SI Materials and Methods). The ability of
fH to decay preformed convertase on ShEA-C3b, or catalyze inactivation of C3b
to iC3b by fI before convertase formation, was assessed by extent of hemolysis.
Complotype assays. CombinedeffectofC3andfBvariantswasassessedusingthe
assaydescribedabove.C3bwasdepositedonShEAusingNHSΔC3BwithC3add-
back; different concentrations (6nM–1.5μM)ofeither fB32Qor fB32Rwereused
to form convertase with either C3b102R or C3b102G. Combined effect of C3 and
fH variants was assessed using cofactor assays with either fH62I or fH62V.
Combined effect of all three variant proteins (C3R102G, fBR32Q, and fHV62I) was
assessed using NHSΔC3BH with C3 add-back to deposit C3b on ShEA, in-
cubation in AP buffer with fI as described for the cofactor assay, and in-
cubation with 3.4 nM fH (chosen to yield incomplete cleavage of C3b in the
assay). Cells were resuspended in AP buffer and lysis developed as described
for decay assay, except that varying concentrations of fB variants (1.5–750nM)
were used to form convertase. AH50 was calculated as previously described
using variants added back to NHS-R3ΔBH (SI Materials and Methods).
Surface Plasmon Resonance. All analyses used a Biacore T100 (GE Healthcare),
run inHBS, 0.01% surfactant P20 as described and in SIMaterials andMethods
(34). To assess enzyme kinetics, fB alone (6–788 nM; proenzyme) or fB (3–397
nM) in the presence of 40 nM fD (convertase) was ﬂowed across immobilized
C3b in HBS, 0.01% surfactant P20, 1 mMMgCl2; proenzyme was regenerated
with EDTA and convertase with sDAF (0.3 μM) or rfH1–4 (1 μM). Regulator
binding to C3b [or C3(H20) where stated] was analyzed by ﬂowing varying
concentrations of fH [45 nM–2.9 μMfor C3b; 0.2 μM–28 μMfor C3(H20), rfH1–4
(89 nM–23 μM), sMCP (100 nM–20 μM), or sDAF (0.78–50 μM); for fH interac-
tions, the surfacewas regeneratedwith 10mMsodiumacetate pH4, 1MNaCl.
Decay of AP C3 convertase was assessed by forming equal amounts of
convertase (788 nM fB, 20 nM fD) on each variant C3b surface (1,500 RU) for
150 s. fH, rfH1–4, and sDAF in the range 10–1,000 nM were injected for 90 s,
and accelerated decay was monitored. Reference curves for each concen-
tration of regulator binding the C3b surface were subtracted to adjust for
regulator interaction with C3b alone.
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